A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > ORGANIZATION
ORGANIZATION
- JPMA to Work with IFPMA to Tackle Non-communicable Diseases in Developing World
October 10, 2011
- Speed, Quality of Clinical Trials Have Increased: Mr Kawaguchi of JPMA
October 10, 2011
- Leading Biotech Clusters in Osaka, Munich Sign Partnership Agreement
October 5, 2011
- Permanent Introduction of Premium for New Drug Development Is an Option: Executive Director Miura of JPA
October 3, 2011
- Takeda “Will Be Able to Get Through” Power Shortages: Mr Hasegawa
October 3, 2011
- “Permanent Introduction of Premium for New Drug Development Premature”: CSIMC Member Adachi
September 30, 2011
- JPA, JSHP Announce Glossary of Standard Terminology for Drug Prescriptions
September 30, 2011
- No Correlation Between Drowsiness and Efficacy of 2nd-Generation Antihistamine Drugs: HIRS
September 30, 2011
- JPMA Head Says Industry Will Support Infrastructure Development for Innovative Drug Discovery
September 28, 2011
- JPMA Asks for Continued R&D Tax Credit System
September 26, 2011
- Continuation of Premium for New Drug Development to Depend on Effects on Drug Lag, Drug Development: Mr Shirakawa of Kenporen
September 26, 2011
- FY2010 Deficit 2nd-Biggest Ever: Kenporen
September 26, 2011
- Over 95% of Patients Agree to Investigational Use of Removed Tissues: NCC Chief Director Kayama
September 22, 2011
- FPMAJ Seeks Improved System for Orphan Drug Development, Request to Be Submitted Soon to Health Minister
September 20, 2011
- Discontinue Re-pricing Following Market Expansion: Mr Umeda of PhRMA
September 19, 2011
- NIBIO Project Making Progress in Discovery of Safety Biomarkers for Evaluating Drug Toxicity
September 19, 2011
- Keizai Doyukai’s Hasegawa Has Not Given Up on 5% Corporate Tax Cut
September 14, 2011
- FPMAJ Announces Its Basic Policy on Providing Info. on Drugs Used Off-label
September 13, 2011
- Mr Hasegawa of Keizai Doyukai Welcomes Incoming Noda Administration
September 12, 2011
- Sales of Class 1 OTC Drugs Recovering Since January 2010: JSMI
September 12, 2011
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…